ALSUntangled #67: rituximab

Xiaoyan Li; Carmel Armon; Paul Barkhaus; Benjamin Barnes; Michael Benatar; Tulio Bertorini; Mark Bromberg; Gregory T. Carter; Jesse Crayle; Merit Cudkowicz; Mazen Dimachkie; Eva L. Feldman; Jonathan Glass; Jill Goslinga; Terry Heiman-Patterson; Sartaj Jhooty; Rachel Lichtenstein; Isaac Lund; Christopher Mcdermott; Gary Pattee; Kaitlyn Pierce; Dylan Ratner; Kristiana Salmon; Paul Wicks; Richard Bedlack

doi:10.1080/21678421.2022.2122845

Back

Journal article

Peer reviewed

ALSUntangled #67: rituximab

Xiaoyan Li, Carmel Armon, Paul Barkhaus, Benjamin Barnes, Michael Benatar, Tulio Bertorini, Mark Bromberg, Gregory T. Carter, Jesse Crayle, Merit Cudkowicz, …

Amyotrophic lateral sclerosis and frontotemporal degeneration, Vol.ahead-of-print(ahead-of-print), pp.1-4

2022-09-15

DOI: https://doi.org/10.1080/21678421.2022.2122845

PMID: 36106861

Appears in Miller School of Medicine - Latest Publications

Abstract

ALS

neuroinflammation

off-label treatment

rituximab

ALSUntangled reviews alternative and off-label treatments on behalf of people with ALS who ask about them. Here we review rituximab, a drug which specifically depletes B lymphocytes. We show a current lack of evidence for a role of these cells in ALS progression. The one patient we found who described using Rituximab for their ALS found no benefit. Given all this, and the known serious risks of rituximab, we advise against its use as an ALS treatment.

Metrics

5 Record Views

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration; International collaboration
Citation topics: 1 Clinical & Life Sciences; 1.52 Neurodegenerative Diseases; 1.52.765 Amyotrophic Lateral Sclerosis
Web Of Science research areas: Clinical Neurology
ESI research areas: Neuroscience & Behavior

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: ALSUntangled #67: rituximab
Creators: Xiaoyan Li - Duke University
Carmel Armon - Loma Linda University
Paul Barkhaus - Medical College of Wisconsin
Benjamin Barnes - Augusta University
Michael Benatar - University of Miami
Tulio Bertorini - University of Tennessee Health Science Center
Mark Bromberg - University of Utah
Gregory T. Carter - Washington State University Spokane
Jesse Crayle - Washington University in St. Louis
Merit Cudkowicz - Harvard University
Mazen Dimachkie - University of Kansas
Eva L. Feldman - University of Michigan–Ann Arbor
Jonathan Glass - Emory University
Jill Goslinga - University of California, San Francisco
Terry Heiman-Patterson - Temple University
Sartaj Jhooty - University of North Carolina at Chapel Hill
Rachel Lichtenstein - Ben-Gurion University of the Negev
Isaac Lund - Undergraduate, Green Hope High School, Cary, NC, USA.
Christopher Mcdermott - University of Sheffield
Gary Pattee - University of Nebraska Medical Center
Kaitlyn Pierce - University of North Carolina at Chapel Hill
Dylan Ratner - Undergraduate, Longmeadow High School, Longmeadow, MA, USA.
Kristiana Salmon - The Neurological Institute
Paul Wicks - Advanced Innovative Engineering
Richard Bedlack - Duke University
Publication Details: Amyotrophic lateral sclerosis and frontotemporal degeneration, Vol.ahead-of-print(ahead-of-print), pp.1-4
Publisher: Taylor & Francis
Academic Unit: Miller School of Medicine; UMMG Department of Neurology; UMMG Dept of Neurology - Neuromuscular Disorders Div
Language: English
Resource Type: Journal article
PMID: 36106861
Record Identifier: 991031785547702976